BUZZ-膀胱癌药物中期数据喜人，Relmada Therapeutics 上市前大涨

路透中文

Mar 09

BUZZ-膀胱癌药物中期数据喜人，Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 上市前大涨

3月9日 - ** 药物开发商Relmada Therapeutics RLMD.O股价盘前上涨73%至5.64美元

** 该公司称其膀胱癌实验药物NDV-01在一项中期研究中帮助大多数患者保持了无癌症状态

** 该公司称，在48名高风险患者中，76%的患者在一年后没有患上癌症；95%的患者在某个阶段出现了完全反应

** 公司补充说，没有患者病情恶化，也没有患者需要进行膀胱切除手术；副作用大多较轻

** 膀胱癌发生于膀胱内壁异常细胞的生长；大多数早期病例在治疗后往往会复发

** 公司表示，RLMD 计划在今年晚些时候开始晚期试验，预计在年底前取得初步结果

** 2025 年股价上涨约九倍

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618628052"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618628052\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618628052?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-09 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618628052","market":"us","top_or_hot":-1,"title":"BUZZ-膀胱癌药物中期数据喜人，Relmada Therapeutics 上市前大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-膀胱癌药物中期数据喜人，Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 上市前大涨</title></head><body><p><span>3月9日</span><span> - </span>** 药物开发商Relmada Therapeutics <span>RLMD.O</span>股价盘前上涨73%至5.64美元</p><p>** 该公司称其膀胱癌实验药物NDV-01在一项中期研究中帮助大多数患者保持了无癌症状态</p><p>** 该公司称，在48名高风险患者中，76%的患者在一年后没有患上癌症；95%的患者在某个阶段出现了完全反应</p><p>** 公司补充说，没有患者病情恶化，也没有患者需要进行膀胱切除手术；副作用大多较轻</p><p>** 膀胱癌发生于膀胱内壁异常细胞的生长；大多数早期病例在治疗后往往会复发</p><p>** 公司表示，RLMD 计划在今年晚些时候开始晚期试验，预计在年底前取得初步结果</p><p>** 2025 年股价上涨约九倍 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-膀胱癌药物中期数据喜人，Relmada Therapeutics 上市前大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-膀胱癌药物中期数据喜人，Relmada Therapeutics 上市前大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-09 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-膀胱癌药物中期数据喜人，Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 上市前大涨</title></head><body><p><span>3月9日</span><span> - </span>** 药物开发商Relmada Therapeutics <span>RLMD.O</span>股价盘前上涨73%至5.64美元</p><p>** 该公司称其膀胱癌实验药物NDV-01在一项中期研究中帮助大多数患者保持了无癌症状态</p><p>** 该公司称，在48名高风险患者中，76%的患者在一年后没有患上癌症；95%的患者在某个阶段出现了完全反应</p><p>** 公司补充说，没有患者病情恶化，也没有患者需要进行膀胱切除手术；副作用大多较轻</p><p>** 膀胱癌发生于膀胱内壁异常细胞的生长；大多数早期病例在治疗后往往会复发</p><p>** 公司表示，RLMD 计划在今年晚些时候开始晚期试验，预计在年底前取得初步结果</p><p>** 2025 年股价上涨约九倍 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX13D:1","article_id":"2618628052","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618628052","pubTimestamp":1773055983,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"BUZZ-Bladder cancer drug mid-term data is gratifying, Relmada Therapeutics surges ahead of launch","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9},"content_text":"BUZZ-膀胱癌药物中期数据喜人，Relmada Therapeutics 上市前大涨3月9日 - ** 药物开发商Relmada Therapeutics RLMD.O股价盘前上涨73%至5.64美元** 该公司称其膀胱癌实验药物NDV-01在一项中期研究中帮助大多数患者保持了无癌症状态** 该公司称，在48名高风险患者中，76%的患者在一年后没有患上癌症；95%的患者在某个阶段出现了完全反应** 公司补充说，没有患者病情恶化，也没有患者需要进行膀胱切除手术；副作用大多较轻** 膀胱癌发生于膀胱内壁异常细胞的生长；大多数早期病例在治疗后往往会复发** 公司表示，RLMD 计划在今年晚些时候开始晚期试验，预计在年底前取得初步结果** 2025 年股价上涨约九倍 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}